Derivation Web

source_e90f336af27e4a3b

by researka:v2 · 2026-07-02 12:52:13.160551+04:00

# Research Synthesis: Aerobic Exercise Training Effects — full paper

## Abstract

This paper synthesizes evidence on aerobic exercise training effects across 39 accepted source papers and 1715 high-confidence extracted claims.

The evidence profile contains 13 direct clinical sources, 26 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence, with a high-density pairwise disagreement map across the evidence base.

Positive study-level signals are summarized in the cardiometabolic, contextual adjacent evidence and muscle function outcome classes, null signals in the contextual adjacent evidence, cardiometabolic and muscle function outcome classes, and negative signals in the cardiometabolic outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that aerobic exercise training effects remains a bounded evidence case: the retained direct, adjacent, and context evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified broad clinical claim.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

## Introduction

This synthesis evaluates evidence on aerobic exercise training effects across 39 included source papers and 1715 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 13 direct clinical sources, 26 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.

### Scope of the synthesis

This synthesis treats the topic as a structured research question
rather than as a binary endorsement. The introduction therefore frames
why the intervention is scientifically relevant, why the evidence base
must be separated by directness and outcome class, and why mechanistic
plausibility cannot substitute for clinical certainty. The public
argument is intentionally bounded: it asks what the accepted evidence
can support, what remains unresolved, and what kind of future study
would most efficiently reduce uncertainty.

## Background

The background evidence for aerobic exercise training effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as MoralesPalomo 2023, Kleinloog 2022, Sloan 2018 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the cardiometabolic, contextual adjacent evidence and muscle function outcome classes; null signals around the contextual adjacent evidence, cardiometabolic and muscle function outcome classes; and negative or adverse signals around the cardiometabolic outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

## Methods

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-aerobic_exercise_training_effects-v06-DAILY-2026-07-02T08-31-19Z-R2`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-02.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `aerobic exercise training effects aging`
- `aerobic exercise training effects older adults`
- `aerobic exercise training effects randomized controlled trial`
- `aerobic exercise training aging`
- `aerobic exercise training older adults`
- `aerobic exercise training randomized controlled trial`

### Eligibility criteria
- Sources whose primary content addresses aerobic exercise training effects.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 190 records in the receipt-candidate union, 70 were classified as source candidates and 39 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

### source admission funnel

| Admission bucket | n |
|---|---:|
| source candidate union | 190 |
| Classified source candidates | 70 |
| No extractable claims | 6 |
| None-only claim binding | 6 |
| Mixed partial-or-none claim-binding candidates | 76 |
| Partial-only claim-binding candidates | 17 |
| Strict high-confidence sources | 15 |
| Admitted final sources | 39 |

### Exclusion reasons
- No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, immune and inflammation, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Evidence Landscape

Directional coding note: Null or no extracted directional signal means no coded positive, negative, or mixed effect was extracted for that specific outcome class; it is not an absence-of-support finding. Positive, negative, mixed, unclear, and null are outcome-specific codes, so a bounded rationale can be supported by adjacent or different outcome evidence while another outcome remains null or unclear. Contextual claims contain bibliographic background, mechanism, methods, exposure definitions, or population context rather than effect-direction evidence. When an outcome-class summary uses no extracted directional signal, it should state the source proportion, such as X/Y sources, to avoid ambiguity. Majority-direction note: 19/39 retained sources are coded unclear at the receipt level. Unless the extraction records a positive, negative, mixed, or null polarity for the mapped outcome, the manuscript states that direction cannot be determined for that source and narrows the conclusion instead of treating source count as directional support. Directional-map boundary: Because 19/39 retained sources are predominantly unclear-coded at receipt level, the corpus does not support a standalone per-class directional map; source-level p-values and polarity are reported as audit facts rather than efficacy directions unless extraction records polarity.

### Findings Map

Findings Map completeness note: all 39 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

Findings Map accounting note: each outcome-class n, direction count, directness count, and source roster is computed from the same source-level rows listed in the detailed table. Receipt-level direction is not a statement that the source abstracts lack directional statistics; it is the conservative coded polarity used for synthesis accounting. Outcome-class roster: Cardiometabolic n=15 (direction: negative=1; null=4; positive=3; unclear=7; directness: direct=3; indirect=4; protocol=1; review=7; sources: Alzahrani 2023; Burchert 2022; Ding 2025; Gelinas 2017; Han 2016; Healy 2024; Konopka 2019; Li 2024; MoralesPalomo 2023; Prior 2014; Rajabi 2024; Silva 2023; Swift 2012; Tanaka 2018; Wyngaert 2018); Contextual Adjacent Evidence n=13 (direction: negative=2; null=4; positive=1; unclear=6; directness: direct=5; indirect=5; review=3; sources: Bakali 2023; Davis 2017; Ehlers 2025; Gaitan 2021; Hansen 2021; Hugenschmidt 2019; Kleinloog 2022; Kobayashi 2021; Morita 2019; Pawar 2025; Raichlen 2020; Wood 2023; Zhou 2026); Muscle Function n=5 (direction: null=3; positive=1; unclear=1; directness: direct=3; indirect=2; sources: Alkhateeb 2020; Jannas-Vela 2023; Liu-Ambrose 2010; Lo 2021; Santos 2024); Immune and Inflammation n=3 (direction: mixed=1; null=1; unclear=1; directness: direct=1; indirect=1; review=1; sources: Emmel 2025; Ghojazadeh 2024; Sloan 2018); Safety and Comorbidity n=2 (direction: null=2; directness: direct=1; indirect=1; sources: Jespersen 2023; Oliveira 2018); Deficiency Prevalence n=1 (direction: unclear=1; directness: review=1; sources: ZURE 2025).



| Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding |
| --- | --- | --- | --- | --- | --- | --- |
| Cardiometabolic | Alzahrani 2023: Feasibility and Efficacy of Low-to-Moderate Intensity Aerobic Exercise Training in Reducing Resting Blood Pressure in Sedentary Older Saudis with Hypertension Living in Social Home Care: A Pilot Randomized Controlled Trial | direction=positive | directness=direct | A1 | outcome=Cardiometabolic; direction=positive | finding=representative statistic p = 0.001; source-level statistic reported |
| Cardiometabolic | Burchert 2022: Aerobic Exercise Training Response in Preterm-Born Young Adults with Elevated Blood Pressure and Stage 1 Hypertension: A Randomized Clinical Trial | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=representative non-significant statistic P = 0.32; not treated as positive or negative directional support unless source direction is coded |
| Cardiometabolic | Ding 2025: Effects of Aerobic Exercise Training in Hypoxia Versus Normoxia on Body Composition and Metabolic Health in Overweight and/or Obese Populations: an Updated Meta-Analysis | direction=unclear | directness=review | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic p < 0.05; source-level statistic reported |
| Cardiometabolic | Gelinas 2017: Aerobic exercise training does not alter vascular structure and function in chronic obstructive pulmonary disease. | direction=null | directness=review | B1 | outcome=Cardiometabolic; direction=null | finding=2 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Han 2016: Association of serum myokines and aerobic exercise training in patients with spinal cord injury: an observational study | direction=unclear | directness=indirect | B2 | outcome=Biomarker/Adjacent Cardiometabolic; direction=unclear | finding=representative statistic p < 0.05; source-level statistic reported |
| Cardiometabolic | Healy 2024: The Effects of Aerobic Exercise Training on Testosterone Concentration in Individuals Who are Obese or Have Type 2 Diabetes: A Systematic Review and Meta-Analysis | direction=unclear | directness=review | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic p < 0.001; source-level statistic reported |
| Cardiometabolic | Konopka 2019: Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic p < 0.05; source-level statistic reported |
| Cardiometabolic | Li 2024: The effect of moderate and vigorous aerobic exercise training on the cognitive and walking ability among stroke patients during different periods: A systematic review and meta-analysis | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=12 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | MoralesPalomo 2023: Efficacy of morning versus afternoon aerobic exercise training on reducing metabolic syndrome components: A randomized controlled trial | direction=positive | directness=direct | A1 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P = 0.002; source-level statistic reported |
| Cardiometabolic | Prior 2014: Increased Skeletal Muscle Capillarization After Aerobic Exercise Training and Weight Loss Improves Insulin Sensitivity in Adults With IGT | direction=positive | directness=indirect | B2 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P < 0.05; source-level statistic reported |
| Cardiometabolic | Rajabi 2024: The effect of 12 weeks of aerobic exercise training with or without saffron supplementation on diabetes‐specific markers and inflammation in women with type 2 diabetes: A randomized double‐blind placebo‐controlled trial | direction=unclear | directness=review | B2 | outcome=Biomarker/Adjacent Cardiometabolic; direction=unclear | finding=representative statistic p < 0.001; source-level statistic reported |
| Cardiometabolic | Silva 2023: Anodal transcranial direct current stimulation associated with aerobic exercise on the functional and physical capacity of patients with heart failure with reduced ejection fraction: ELETRIC study protocol | direction=null | directness=protocol | D1 | outcome=Cardiometabolic; direction=null | finding=18 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Swift 2012: The effect of different doses of aerobic exercise training on endothelial function in postmenopausal women with elevated blood pressure: results from the DREW study. | direction=negative | directness=review | B1 | outcome=Cardiometabolic; direction=negative | finding=representative statistic p<0.001; source-level statistic reported |
| Cardiometabolic | Tanaka 2018: The impact of aerobic exercise training with vascular occlusion in patients with chronic heart failure | direction=null | directness=indirect | B2 | outcome=Cardiometabolic; direction=null | finding=14 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Wyngaert 2018: The effects of aerobic exercise on eGFR, blood pressure and VO 2 peak in patients with chronic kidney disease stages 3-4: A systematic review and meta-analysis | direction=unclear | directness=review | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic p<0.001; source-level statistic reported |
| Contextual Adjacent Evidence | Bakali 2023: Effect of aerobic exercise training on pulse wave velocity in adults with and without long-term conditions: a systematic review and meta-analysis | direction=unclear | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic p<0.0001; source-level statistic reported |
| Contextual Adjacent Evidence | Davis 2017: Economic evaluation of aerobic exercise training in older adults with vascular cognitive impairment: PROMoTE trial | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=19 extracted claim(s); receipt-level direction is the coded finding |
| Contextual Adjacent Evidence | Ehlers 2025: Enhancing cognitive function in breast cancer survivors through community-based aerobic exercise training: protocol for a Hybrid Type I effectiveness–implementation study employing a randomised controlled design | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=10 extracted claim(s); receipt-level direction is the coded finding |
| Contextual Adjacent Evidence | Gaitan 2021: Effects of Aerobic Exercise Training on Systemic Biomarkers and Cognition in Late Middle-Aged Adults at Risk for Alzheimer’s Disease | direction=negative | directness=indirect | B2 | outcome=Biomarker/Adjacent Evidence; direction=negative | finding=representative statistic p < 0.01; source-level statistic reported |
| Contextual Adjacent Evidence | Hansen 2021: Effect of aerobic exercise training on asthma control in postmenopausal women (the ATOM-study): protocol for an outcome assessor, randomised controlled trial | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=15 extracted claim(s); receipt-level direction is the coded finding |
| Contextual Adjacent Evidence | Hugenschmidt 2019: Cognitive effects of adding caloric restriction to aerobic exercise training in older adults with obesity | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic p=0.01; source-level statistic reported |
| Contextual Adjacent Evidence | Kleinloog 2022: Aerobic exercise training improves not only brachial artery flow‐mediated vasodilatation but also carotid artery reactivity: A randomized controlled, cross‐over trial in older men | direction=positive | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=positive | finding=representative statistic p = 0.012; source-level statistic reported |
| Contextual Adjacent Evidence | Kobayashi 2021: The Effect of Aerobic Exercise Training Frequency on Arterial Stiffness in a Hyperglycemic State in Middle-Aged and Elderly Females | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic p < 0.05; source-level statistic reported |
| Contextual Adjacent Evidence | Morita 2019: Aerobic Exercise Training with Brisk Walking Increases Intestinal Bacteroides in Healthy Elderly Women | direction=negative | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=negative | finding=representative statistic p = 0.004; source-level statistic reported |
| Contextual Adjacent Evidence | Pawar 2025: Effectiveness of aerobic exercise training in patients with obstructive sleep apnea: a systematic review and meta-analysis | direction=unclear | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic p < 0.00001; source-level statistic reported |
| Contextual Adjacent Evidence | Raichlen 2020: Effects of simultaneous cognitive and aerobic exercise training on dual-task walking performance in healthy older adults: results from a pilot randomized controlled trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic p = 0.048; source-level statistic reported |
| Contextual Adjacent Evidence | Wood 2023: Estimating the Effect of Aerobic Exercise Training on Novel Lipid Biomarkers: A Systematic Review and Multivariate Meta-Analysis of Randomized Controlled Trials | direction=unclear | directness=review | B2 | outcome=Biomarker/Adjacent Evidence; direction=unclear | finding=representative statistic P = .01; source-level statistic reported |
| Contextual Adjacent Evidence | Zhou 2026: Telemedicine-based individualised aerobic exercise training in Chinese adults with inactive or mildly active inflammatory bowel disease: study protocol for a single-centre, semi-crossover randomised controlled trial | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=8 extracted claim(s); receipt-level direction is the coded finding |
| Deficiency Prevalence | ZURE 2025: The effect of blood flow restricted aerobic exercise training on pain, functional status, quality of life and hormonal response to exercise in fibromyalgia patients: a randomized double-blind study | direction=unclear | directness=review | B2 | outcome=Deficiency Prevalence; direction=unclear | finding=representative statistic P<0.001; source-level statistic reported |
| Immune and Inflammation | Emmel 2025: Feasibility of an unsupervised aerobic exercise training program for participants with persistent symptoms after SARS-CoV-2 infection | direction=null | directness=indirect | B2 | outcome=Immune and Inflammation; direction=null | finding=67 extracted claim(s); receipt-level direction is the coded finding |
| Immune and Inflammation | Ghojazadeh 2024: The effects of aerobic exercise training on inflammatory markers in adult tobacco smokers: A systematic review and meta-analysis of randomized controlled trials. | direction=unclear | directness=review | B1 | outcome=Biomarker/Adjacent Immune and Inflammation; direction=unclear | finding=representative statistic P = 0.05; source-level statistic reported |
| Immune and Inflammation | Sloan 2018: Aerobic Exercise Training and Inducible Inflammation: Results of a Randomized Controlled Trial in Healthy, Young Adults | direction=mixed | directness=direct | A1 | outcome=Immune and Inflammation; direction=mixed | finding=representative non-significant statistic P =0.08; not treated as positive or negative directional support unless source direction is coded |
| Muscle Function | Alkhateeb 2020: Effects of football versus aerobic exercise training on muscle architecture in healthy men adults: a study protocol of a two-armed randomized controlled trial | direction=null | directness=direct | A1 | outcome=Muscle Function; direction=null | finding=12 extracted claim(s); receipt-level direction is the coded finding |
| Muscle Function | Jannas-Vela 2023: Role of specialized pro-resolving mediators on inflammation, cardiometabolic health, disease progression, and quality of life after omega-3 PUFA supplementation and aerobic exercise training in individuals with rheumatoid arthritis: a randomized 16-week, placebo-controlled interventional trial * | direction=null | directness=indirect | B2 | outcome=Muscle Function; direction=null | finding=6 extracted claim(s); receipt-level direction is the coded finding |
| Muscle Function | Liu-Ambrose 2010: Promotion of the mind through exercise (PROMoTE): a proof-of-concept randomized controlled trial of aerobic exercise training in older adults with vascular cognitive impairment | direction=null | directness=direct | A1 | outcome=Muscle Function; direction=null | finding=1 extracted claim(s); receipt-level direction is the coded finding |
| Muscle Function | Lo 2021: Effects of Individualized Aerobic Exercise Training on Physical Activity and Health-Related Physical Fitness among Middle-Aged and Older Adults with Multimorbidity: A Randomized Controlled Trial | direction=positive | directness=direct | A1 | outcome=Muscle Function; direction=positive | finding=representative statistic p = 0.011; source-level statistic reported |
| Muscle Function | Santos 2024: Aerobic exercise training combined with local strength exercise restores muscle blood flow and maximal aerobic capacity in long-term Hodgkin lymphoma survivors | direction=unclear | directness=indirect | B2 | outcome=Muscle Function; direction=unclear | finding=representative statistic P = 0.013; source-level statistic reported |
| Safety and Comorbidity | Jespersen 2023: Effect of aerobic exercise training on the fat fraction of the liver in persons with chronic hepatitis B and hepatic steatosis: Trial protocol for a randomized controlled intervention trial— The FitLiver study | direction=null | directness=direct | A1 | outcome=Safety and Comorbidity; direction=null | finding=12 extracted claim(s); receipt-level direction is the coded finding |
| Safety and Comorbidity | Oliveira 2018: Safety and Efficacy of Aerobic Exercise Training Associated to Non-Invasive Ventilation in Patients with Acute Heart Failure | direction=null | directness=indirect | B2 | outcome=Safety and Comorbidity; direction=null | finding=representative statistic p < 0.05; source-level statistic reported |

## Results

**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.


| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Aerobic Exercise Training Effects / Cardiometabolic | n=15; claims=874 | significant source statistic in 10/15 sources; receipt-level direction coded unclear | 3 direct; 4 indirect; 1 protocol; 7 review | limited corpus depth in this outcome class |
| Aerobic Exercise Training Effects / Contextual Adjacent Evidence | n=13; claims=468 | significant source statistic in 9/13 sources; receipt-level direction coded unclear | 5 direct; 5 indirect; 3 review | limited corpus depth in this outcome class |
| Aerobic Exercise Training Effects / Muscle Function | n=5; claims=106 | significant source statistic in 2/5 sources; receipt-level direction coded null | 3 direct; 2 indirect | limited corpus depth in this outcome class |
| Aerobic Exercise Training Effects / Immune and Inflammation | n=3; claims=189 | significant source statistic in 1/3 sources; receipt-level direction coded unclear | 1 direct; 1 indirect; 1 review | limited corpus depth in this outcome class |
| Aerobic Exercise Training Effects / Safety and Comorbidity | n=2; claims=59 | significant source statistic in 1/2 sources; receipt-level direction coded null | 1 direct; 1 indirect | limited corpus depth in this outcome class |
| Aerobic Exercise Training Effects / Deficiency Prevalence | n=1; claims=19 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 review | single-source slice; hypothesis-generating |

**Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect.
- Aging and geroscience context: 8 sources; significant source statistic in 6/8 sources; receipt-level direction coded unclear.
- Skeletal and muscle context: 5 sources; significant source statistic in 3/5 sources; receipt-level direction coded unclear.
- Oncology and cancer context: 1 sources; no extracted directional signal in 1/1 sources.
- Pulmonary and rare-disease context: 1 sources; no extracted directional signal in 1/1 sources.

### Results Summary

- Cardiometabolic: n=15; claims=874; mixed signal in 8/15 sources | directness: 3 direct; 4 indirect; 7 review; 1 protocol; main limitation: directionally heterogeneous.
- Contextual Adjacent Evidence: n=13; claims=468; mixed signal in 8/13 sources | directness: 5 direct; 5 indirect; 3 review; main limitation: directionally heterogeneous.
- Muscle Function: n=5; claims=106; no extracted directional signal in 3/5 sources | directness: 3 direct; 2 indirect; main limitation: directionally heterogeneous.
- Immune and Inflammation: n=3; claims=189; mixed signal in 1/3 sources | directness: 1 direct; 1 indirect; 1 review; main limitation: directionally heterogeneous.
- Safety and Comorbidity: n=2; claims=59; no extracted directional signal in 2/2 sources | directness: 1 direct; 1 indirect; main limitation: population and endpoint heterogeneity.
- Deficiency Prevalence: n=1; claims=19; mixed signal in 1/1 sources | directness: 1 review; main limitation: no direct clinical anchor.

### Cardiometabolic Outcomes


Three direct clinical RCTs anchor the cardiometabolic evidence. Alzahrani 2023 conducted a pilot RCT in sedentary older Saudis with hypertension living in social home care, delivering eight weeks of mild-to-moderate aerobic exercise and reporting reductions in resting blood pressure.

The quantitative findings diverge across these direct trials, as documented per study in the evidence synthesis. Burchert 2022 returns uniformly null cardiometabolic contrasts at P = 0.32, P = 0.12, P = 0.13, P = 0.06, P = 0.58, P = 0.56, P = 0.61, and P = 0.44 — a directly negative functional signal that contrasts with the positive findings in MoralesPalomo 2023 (e.

Mechanistically, the indirect clinical cohorts and metabolic reviews indicate substrate-level pathways compatible with the positive RCT signals. Konopka 2019 added a negative-direction mechanistic signal in older adults, reporting that metformin attenuated mitochondrial and cardiorespiratory adaptations to aerobic training, with effects at P < 0.05, P < 0.001, P < 0.01, and null comparisons at P = 0.08, P = 0.02, P = 0.07, P = 0.06.

Because the bundle sources on immune/inflammation, metformin–exercise interaction, and the Swift 2012 review were not advanced into the safety comorbidity class (each belongs to cardiometabolic or immune-related outcome classes per the source schema), the safety comorbidity subsection here is intentionally narrow.

### Deficiency Prevalence Outcomes


Within the curated corpus on aerobic exercise training effects, the single direct evidence entry targeting a deficiency-prevalence or symptom-burden outcome class is the ZURE 2025 randomized double-blind study, which examined blood flow restricted (BFR) aerobic exercise training in fibromyalgia patients and reported change across pain, functional status, quality of life, and hormonal response to exercise as its pre-specified endpoints [ZURE 2025]. The study design was a randomized double-blind trial in adults, framing BFR-aerobic training as an intervention intended to reduce the symptom burden of fibromyalgia rather than to alter a discrete biochemical deficiency state. Because the source specifies a review-graded directness label for this outcome class, the trial functions in the synthesis as a context-of-effect exemplar rather than as a primary prevalence estimator.

Several of these (P < 0.001, P = 0.049, P = 0.040, P = 0.002) reach conventional significance, while the remaining values (P = 0.121, P = 0.084, P = 0.480, P = 0.823, P = 0.559) do not. Per the source, both arms showed improvements across the outcome battery, and the BFR-aerobic arm's incremental benefit is captured in the contrast terms rather than in a single global p-value. The effect direction field is recorded as unclear, reflecting that the source does not specify a uniform direction across the multi-endpoint panel.

Mechanistically, the ZURE 2025 design combines aerobic exercise training with blood-flow restriction, which the broader corpus treats as a route to amplified musculoskeletal and hormonal load at lower external workloads, plausibly explaining why BFR-aerobic protocols register on pain and functional-status scales in fibromyalgia. The source-level directness label of 'review' positions this study at the contextual-extrapolation tier rather than as a mechanistic human-substrate study, so the mechanistic account here is descriptive rather than biochemical. In the framework of the brief, this outcome class is best read as a symptom-burden signal rather than as evidence on a hard deficiency endpoint.

Within-corpus tensions in the deficiency-prevalence class cannot be enumerated from same-outcome non-orthogonal pairs because the cross-study disagreement map records no non-orthogonal pairings within this outcome class. The honest reading is that the deficiency-prevalence signal in this corpus is provisional and rests on one trial with a multi-endpoint, mixed-significance profile.

### Immune and Inflammation Outcomes


The immune-outcome evidence in this corpus is anchored by one direct randomized controlled trial and one aggregating systematic review. Together these two sources define the immune class within the corpus.

Mechanistically, the immune class integrates a clinical RCT design (Sloan 2018) with an aggregating review-level synthesis in a defined inflammatory-prone population (Ghojazadeh 2024). The mechanistic substrate underlying this functional finding is the inducible inflammation pathway, where biomarker readouts in healthy young adults after aerobic training (Sloan 2018) are positioned against pooled estimates in adult tobacco smokers, a population with a different baseline inflammatory load (Ghojazadeh 2024). Preclinical-style stratification is therefore absent here; the class is human-only, with one direct trial and one indirect review contributing the available signal.

Within-corpus tension is driven by an indirectness gap between the two immune-class sources rather than by directional disagreement on a shared endpoint. Sloan 2018 is a direct randomized trial measuring inducible inflammation in healthy young adults and reports a mix of null and significant p-values across multiple biomarkers, whereas Ghojazadeh 2024 is a review-level synthesis in adult tobacco smokers that reports P = 0.05 for a pooled inflammatory marker effect. Because the two sources address different populations (healthy adults vs adult tobacco smokers) and operate at different evidence levels (direct trial vs review), the apparent divergence is best interpreted as a population- and design-level gap rather than a contradiction between two trials measuring the same endpoint. The per-source tally within the immune class is therefore two sources, with no third source currently contributing outcome-class-specific immune evidence beyond what is enumerated in the evidence synthesis.

Because the design is observational and the source carries no reported p-values or effect-direction assignment, the evidence within this outcome class reduces to a single feasibility-focused pilot that does not, on its own, quantify immune or inflammatory endpoints (Emmel 2025). Directness is rated indirect relative to a clinical inflammation endpoint, since adherence and program tolerance are upstream of any downstream immunologic measurement (Emmel 2025).

Quantitatively, Emmel 2025 supplies no numeric effect size, no p-value, and no reported direction of effect; the source's effect direction is recorded as null and p values is empty, so any numeric claim about immune or inflammatory change attributable to the aerobic program cannot be supported from this source alone (Emmel 2025).

Mechanistically, an aerobic-training stimulus in a post-viral cohort is biologically plausible to modulate inflammation through canonical pathways, but the source does not measure those pathways and so the mechanistic argument remains qualitative rather than source-traced (Emmel 2025).

Per the integrating brief, additional bundle members (Sloan 2018, Ghojazadeh 2024) are catalogued in the structured evidence table but are not used as load-bearing numerics in this subsection, in order to keep the narrative coherent with the sources actually invoked (Emmel 2025).

The mechanistic substrate underlying any expected anti-inflammatory effect of aerobic training is described qualitatively here, because no source in the immune inflammation class reports cytokine, CRP, or immune-cell numerics: human RCT and mechanistic data in adjacent bundles suggest plausible anti-inflammatory adaptation, but those signals are not source-traced in this outcome class and therefore cannot be reported as numeric findings (Emmel 2025). The within-corpus tension in this class is therefore minimal in numeric terms — there is only one directness-indirect observational source and no non-orthogonal pair is recorded in the cross-study disagreement map for immune inflammation — and the principal interpretive tension is between the feasibility framing of the pilot and the broader reader expectation of inflammatory-endpoint reporting, which the source itself does not address (Emmel 2025). The clinical RCT literature that would normally resolve this interpretive tension is not represented in the curated bundle for this outcome class, so the subsection closes with an explicit gap statement rather than an over-claimed summary.

Evidence for this outcome class is represented in the structured results table, but the retained narrative paragraphs were more strongly assigned to adjacent outcome classes. The synthesis therefore treats this class as context for cross-domain interpretation rather than as a standalone prose claim.

### Muscle Function Outcomes


Five sources populate the muscle function evidence class, spanning clinical RCTs and observational cohorts across older adults, adults, and clinical-survivor populations. Lo 2021 is a clinical RCT in middle-aged and older adults with multimorbidity testing individualized aerobic exercise training combined with another modality and reports a battery of positive changes on physical-activity and health-related fitness endpoints (see the evidence synthesis for the full per-study endpoint list, including P = 0.011, P = 0.007, P = 0.019, P = 0.027, P = 0.043, P = 0.001, P = 0.018, P = 0.025, P = 0.028, P = 0.030, P = 0.002, P = 0.012, and P = 0.004). Santos 2024 is an observational cohort in long-term Hodgkin lymphoma survivors combining aerobic training with local strength exercise, with reported p-values ranging from P < 0.001 through P = 0.001 and P = 0.002 to P = 0.054, P = 0.035, P = 0.037, P = 0.016, P = 0.044, P = 0.020, and three null/near-null values at P = 0.740, P = 0.742, and P = 0.643. Alkhateeb 2020, Liu-Ambrose 2010, and Jannas-Vela 2023 contribute no extractable p-values in the current source bundle.

Quantitative findings diverge by source. Lo 2021 contributes thirteen statistically significant p-values (range P = 0.001 to P = 0.043) on muscle-function and fitness endpoints, consistent with its positive effect direction label. Alkhateeb 2020, Liu-Ambrose 2010, and Jannas-Vela 2023 report no p-values in the source bundle and carry null or unclear effect direction labels. The full per-study endpoint evidence is summarized in the evidence synthesis (Per-Study Endpoint Evidence) rather than restated here.

Mechanistically, the positive signal in Lo 2021 (clinical RCT, direct endpoint) aligns with a plausible substrate in which aerobic training drives vascular, mitochondrial, and neuromuscular adaptations that translate to measurable strength and fitness gains in older adults with multimorbidity. Santos 2024 (observational cohort, indirect endpoint) reports restoration of muscle blood flow and maximal aerobic capacity after combined aerobic plus local strength exercise in long-term Hodgkin lymphoma survivors, providing a mechanistic human-data signal that converges with Lo 2021 on the vascular–mitochondrial axis but in a much narrower clinical-survivor population. Preclinical data were not represented in the source bundle for this outcome class, so the mechanistic substrate here rests on the two human studies and on canonical exercise-physiology principles that the sources cite but do not themselves enumerate.

Within-corpus tensions are prominent in muscle function. The strongest conflict pairs Lo 2021 (positive, direct) against Liu-Ambrose 2010 (null, direct) and against Alkhateeb 2020 (null, direct), a null-vs-positive disagreement on clinically and functionally direct endpoints that is only partially resolvable on the available information: Lo 2021 enrolled middle-aged and older adults with multimorbidity, whereas Liu-Ambrose 2010 enrolled older adults with vascular cognitive impairment, and Alkhateeb 2020 enrolled healthy men adults comparing football versus aerobic exercise, so population and comparator differences likely contribute. A second, orthogonal tension layer is the indirectness gap between the three direct RCTs (Lo 2021, Liu-Ambrose 2010, Alkhateeb 2020) and the two indirect observational/interventional sources (Santos 2024, Jannas-Vela 2023), which the synthesis must keep analytically separate rather than average. Together these tensions support the brief's integrating framing that the aerobic-exercise-training case for muscle function is context-dependent rather than uniformly positive or null.

### Safety and Comorbidity Outcomes


In a clinical RCT, Jespersen 2023 evaluated the effect of aerobic exercise training on hepatic fat fraction in adults with chronic hepatitis B and hepatic steatosis, constituting a direct, A1-grade mechanistic/biomarker trial designed to quantify liver-tissue response to a 12-week aerobic intervention. The trial design is human and direct, allowing inference about hepatic-comorbidity endpoints rather than surrogate physiological markers, and the source carries no effect-direction tag, indicating the design is positioned to detect either improvement or null. The mechanistic substrate underlying this safety/comorbidity endpoint is adipose-tissue and hepatic lipid turnover, which is modulated by aerobic training intensity and duration, and the source therefore reports a per-protocol endpoint (hepatic fat fraction) rather than a composite safety event.

Mechanistically, the within-corpus source documents an acute-heart-failure population in whom aerobic work is delivered alongside ventilatory support, distinguishing this evidence from a stable outpatient cohort.

The directness gap between Jespersen 2023 and Oliveira 2018 on safety comorbidity is a genuine within-corpus tension and is treated as such: a direct mechanistic/biomarker trial (Jespersen 2023) cannot be merged with an indirect bundled-intervention cohort (Oliveira 2018) because the latter's effect cannot be attributed to aerobic training alone. The source-level theses differ in directionality handling — Jespersen 2023's effect direction field is null (pre-specified biomarker endpoint awaiting result), whereas Oliveira 2018 is also tagged null at the safety-class level even though its 6MWT functional sub-endpoint shows a positive Δ, indicating that the source classifies the trial as a safety/comorbidity study rather than a functional-capacity study. Readers should therefore interpret Oliveira 2018 as evidence about safety of an aerobic-plus-NIV bundle, not as evidence about aerobic training per se.

Direction reconciliation: source-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction.

### Contextual Adjacent Evidence Outcomes


Davis 2017 reports a 6-month thrice-weekly progressive aerobic programme versus usual care in older adults with vascular cognitive impairment, with a 6-month post-intervention follow-up assessment, and Raichlen 2020 randomized n = 74 healthy older adults across four arms (cognitive training, aerobic exercise, combined, control) and reported a dual-task walking performance contrast of P = 0.048.

Contextual Adjacent Evidence remains a separate Results slice for Aerobic Exercise Training Effects (n=13; claims=468; significant source statistic in 9/13 sources; receipt-level direction coded unclear; 5 direct; 5 indirect; 3 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Kleinloog 2022 (Aerobic exercise training improves not only brachial artery flow‐mediated vasodilatation but also carotid artery; representative statistic p = 0.012; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=positive; directness=direct; tier=A1).
- Raichlen 2020 (Effects of simultaneous cognitive and aerobic exercise training on dual-task walking performance in healthy older; representative statistic p = 0.048; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1).
- Kobayashi 2021 (The Effect of Aerobic Exercise Training Frequency on Arterial Stiffness in a Hyperglycemic State in Middle-Aged and; representative statistic p < 0.05; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2).
- Hugenschmidt 2019 (Cognitive effects of adding caloric restriction to aerobic exercise training in older adults with obesity; representative statistic p=0.01; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2).

## Cross-Domain Synthesis

The most consequential cross-domain tension in this corpus is the gap between mechanistic/biomarker RCTs of aerobic exercise training (AET) and the clinically anchored functional RCTs in the cardiometabolic class. On the mechanistic side, Kleinloog 2022 is a direct RCT reporting positive effects on carotid artery reactivity (with several p-values in the 0.001–0.05 range and others including P = 0.830 and P = 0.823), and Wood 2023 is a multivariate meta-analysis reporting that AET significantly raised antiatherogenic apolipoproteins and lipoprotein sub-fractions. These are biomarker/surrogate readouts and, as Ioannidis 2005 cautions, surrogate associations do not guarantee hard-outcome validity. The boundary condition is population: when AET is delivered to adults with active cardiometabolic risk and the endpoint is itself a clinical/biochemical criterion (blood pressure, MetS z-score), benefit is reproducible; when the endpoint is a vascular reactivity index in already healthy older men, mechanistic plausibility is established but clinical translation is not yet proven. The resolution the corpus does not yet supply is a head-to-head trial pairing the same AET protocol against a surrogate and a hard outcome in the same cohort.

Another tension that the within-class summary obscures is the disagreement inside the cardiometabolic class between direct RCTs that report positive effects and at least two sources reporting null or negative cardiometabolic findings, which the prior abstract framing did not integrate. Swift 2012 is coded with effect direction: negative and reports that different doses of AET did not produce the expected improvements in endothelial function in postmenopausal women with elevated blood pressure (DREW trial). Konopka 2019 is coded effect direction: unclear on the metformin–exercise interaction, and Tanaka 2018 reports a null direction on a chronic heart failure cohort. Reconciling this: the positive direct RCTs (MoralesPalomo 2023; Alzahrani 2023) tested protocols in metabolic-syndrome and hypertensive populations against clinical/biochemical endpoints, whereas Swift 2012 and Tanaka 2018 tested endothelial/vascular remodeling endpoints where dose and population (postmenopausal women; chronic heart failure) may blunt the response. The boundary condition is therefore outcome choice and dose–response, not AET itself: surrogate vascular endpoints and low-dose postmenopausal protocols are not equivalent to MetS-component trials. Resolution would require harmonized protocols across both endpoint families.

Another tension sits between the muscle function class and the cardiometabolic class, where the same AET stimulus can produce concordant or discordant effects depending on whether the endpoint is contractile performance or metabolic/vascular remodeling. Lo 2021 (RCT, direct, muscle function) reports positive effects on physical activity and health-related physical fitness in middle-aged and older adults with multimorbidity (P = 0.011 down to P = 0.002 across multiple outcomes). Alkhateeb 2020 is a protocol with effect direction: null on muscle architecture, and Liu-Ambrose 2010 is coded null on muscle function in the PROMoTE vascular cognitive impairment cohort. The boundary condition is disease background and training modality: when AET is added to local strength work in long-term cancer survivors, muscle blood flow and VO2max both rise; when AET is delivered as the sole stimulus in frail older adults with vascular cognitive impairment, contractile gains are less reliable. The corpus therefore supports AET as a muscle-function adjunct but does not support it as a stand-alone muscle-architecture intervention. Resolution would require factorial trials crossing AET × resistance training across frailty strata.

The sixth and overarching tension is one the abstract flagged but did not adjudicate: the contrast between model-organism and surrogate-endpoint plausibility and the sparse hard-outcome human RCTs. Several sources are explicitly protocol-stage (Silva 2023; Hansen 2021; Ehlers 2025; Zhou 2026; Jespersen 2023; Tanaka 2018) or feasibility-stage (Emmel 2025; Davis 2017), meaning that their null or unclear effect direction reflects incomplete data, not absence of effect. The boundary condition implied by the corpus is therefore a hierarchical one: protocol/feasibility sources (Silva 2023, Hansen 2021, Ehlers 2025, Zhou 2026, Jespersen 2023, Tanaka 2018, Emmel 2025, Davis 2017) can support a claim that the field is generating the next wave of trials but cannot yet support a claim about efficacy; only the completed direct RCTs (MoralesPalomo 2023, Alzahrani 2023, Lo 2021, Kleinloog 2022, Sloan 2018, Burchert 2022, Oliveira 2018, Raichlen 2020) can be cited for endpoint-level inference. Resolution of the overarching tension requires hard-outcome RCTs with mortality, hospitalization, or adjudicated healthspan endpoints, which the current corpus does not contain.

### Boundary-condition synthesis

Interpreting the cross-domain evidence requires treating each domain as
part of a boundary-condition map rather than as a single pooled effect. Direct human findings set the clinical perimeter; mechanistic findings
explain plausible pathways; indirect findings identify where transfer
across populations, time horizons, or measurement systems remains
uncertain. This separation is important because evidence can be valid
within one outcome domain while remaining weak support for another. The synthesis therefore gives priority to source-traced clinical
findings when making patient-facing claims, uses mechanistic evidence
to explain why effects might diverge, and treats discordance as a
signal about applicability rather than as a reason to average unlike
endpoints together.

We operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive, null-vs-negative tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.
## Discussion

**Thesis:** Across 39 curated reference papers, the evidence base for Aerobic shows a context-dependent profile. Positive signals appear in: cardiometabolic, contextual other. Negative signals appear in: cardiometabolic. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Aerobic broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

### Evidence Summary

The evidence base for this synthesis comprises 39 included sources. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 3 distinct summaries across the source set: adults; older adults; type 2 diabetes patients. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

### Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus offers no long-term mortality or major-adverse-cardiovascular-event trial of aerobic exercise training in non-diabetic, community-dwelling adults, which is the population in whom headline claims about life-extension or cardiovascular event reduction are most often invoked. The corpus is therefore silent on whether the surrogate signals repeatedly observed — for example MoralesPalomo 2023's significant reductions in metabolic syndrome components and Alzahrani 2023's reductions in resting blood pressure — translate into fewer events, hospitalisations, or deaths over clinically meaningful horizons.

Several outcomes in the cardiometabolic and contextual other classes are supported by only a single source in the corpus, so they cannot be internally replicated and are vulnerable to single-trial generalisation. Where Swift 2012 reports a negative direction and Konopka 2019 reports negative-direction signals for the metformin co-interaction, the overall synthesis cannot adjudicate between true inconsistency and single-trial artefact; downstream conclusions drawn from these cells inherit that fragility.

Population specificity is pronounced and constrains external validity. Women with type 2 diabetes are represented only by Rajabi 2024, and healthy young adults only by Sloan 2018. The corpus contains essentially no adequately powered evidence in healthy young or middle-aged adults without cardiometabolic risk factors, in pregnant women, or in children/adolescents, so claims about 'generally healthy' populations cannot be grounded in the present evidence base.

Endpoint coverage is narrow and concentrates on intermediate physiological and biomarker outcomes rather than patient-important endpoints. The cardiometabolic class is dominated by blood pressure, lipid fractions, glucose/insulin indices, flow-mediated dilatation, and VO2 peak; cognitive outcomes appear only as composite scores in Hugenschmidt 2019 and as dual-task gait in Raichlen 2020 (n=74); hard clinical endpoints — myocardial infarction, stroke, hospitalisation for heart failure, fracture, institutionalisation — are absent. Several entries are protocols with no quantitative results at all (Silva 2023, Hansen 2021, Emmel 2025, Jespersen 2023, Alkhateeb 2020, Ehlers 2025, Zhou 2026, Jannas-Vela 2023), so their inclusion in the corpus cannot contribute effect estimates and they function only as evidence-of-planned-trials, not as evaluable findings.

Several clinically-relevant claims sit on mechanistic or biomarker evidence rather than confirmatory human RCTs, which is a recognised limitation because surrogate associations do not guarantee hard-outcome validity (Ioannidis 2005). These are predominantly mechanistic or biomarker syntheses, and the corpus does not contain an adequately powered RCT confirming that the lipid or vascular surrogates translate into reduced cardiovascular events in the same populations. Effect directions are unclear (n=19), null (n=14), positive (n=4), mixed (n=1), negative (n=1), with 26 sources carrying source-traced p-values and 348 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.

## What This Synthesis Adds

This synthesis maps 39 included sources on Aerobic Exercise Training Effects across 7 outcome classes and a high-density pairwise disagreement map. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

Across 39 curated reference papers, the evidence base for Aerobic shows a context-dependent profile. Positive signals appear in: cardiometabolic, contextual other. Negative signals appear in: cardiometabolic. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis.

Prior reviews in the corpus (Swift 2012, Gelinas 2017, Ghojazadeh 2024) emphasize convergent signals on Aerobic Exercise Training Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| cardiometabolic | 3 | 12 | negative, null, positive, unclear | conflict-resolution gap |
| muscle function | 3 | 2 | null, positive, unclear | conflict-resolution gap |
| deficiency prevalence | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| immune and inflammation | 1 | 1 | mixed, unclear | replication gap |
| immune and inflammation | 0 | 1 | null | direct interventional hard-endpoint gap |
| contextual adjacent evidence | 5 | 8 | null, positive, unclear | conflict-resolution gap |
| safety and comorbidity | 1 | 1 | null | replication gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | cardiometabolic: conflict-resolution gap | 3 direct and 12 indirect sources; direction profile: negative, null, positive, unclear |
| P2 | muscle function: conflict-resolution gap | 3 direct and 2 indirect sources; direction profile: null, positive, unclear |
| P3 | deficiency prevalence: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |
| P4 | immune and inflammation: replication gap | 1 direct and 1 indirect sources; direction profile: mixed, unclear |
| P5 | immune and inflammation: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |

### Next-Study Design Recommendation

The next high-yield study for Aerobic Exercise Training Effects should target the **cardiometabolic** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 100 participants per arm, a priority population of the same population type as the strongest direct source cluster, and follow-up lasting at least 24 weeks; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- MoralesPalomo 2023; tier=A1; directness=direct; endpoint=cardiometabolic; direction=positive; representative statistic=P < 0.001.
- Kleinloog 2022; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P < 0.001.
- Sloan 2018; tier=A1; directness=direct; endpoint=immune; direction=mixed; representative statistic=P < 0.001.
- Alzahrani 2023; tier=A1; directness=direct; endpoint=cardiometabolic; direction=positive; representative statistic=P = 0.001.
- Lo 2021; tier=A1; directness=direct; endpoint=muscle function; direction=positive; representative statistic=P = 0.001.
- Burchert 2022; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=P = 0.06.
- Hansen 2021; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null.
- Alkhateeb 2020; tier=A1; directness=direct; endpoint=muscle function; direction=null.
- Jespersen 2023; tier=A1; directness=direct; endpoint=safety comorbidity; direction=null.
- Ehlers 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null.

### Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

- MoralesPalomo 2023: outcome=cardiometabolic; directness=direct; tier=A1; direction=positive; claims=163.
- Kleinloog 2022: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=positive; claims=161.
- Sloan 2018: outcome=immune; directness=direct; tier=A1; direction=mixed; claims=120.
- Alzahrani 2023: outcome=cardiometabolic; directness=direct; tier=A1; direction=positive; claims=66.
- Lo 2021: outcome=muscle function; directness=direct; tier=A1; direction=positive; claims=54.
- Burchert 2022: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=47.
- Hansen 2021: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=15.
- Alkhateeb 2020: outcome=muscle function; directness=direct; tier=A1; direction=null; claims=12.
- Jespersen 2023: outcome=safety comorbidity; directness=direct; tier=A1; direction=null; claims=12.
- Ehlers 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=10.
- Raichlen 2020: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=8.
- Zhou 2026: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=8.
- Liu-Ambrose 2010: outcome=muscle function; directness=direct; tier=A1; direction=null; claims=1.
- Swift 2012: outcome=cardiometabolic; directness=review; tier=B1; direction=negative; claims=14.
- Gelinas 2017: outcome=cardiometabolic; directness=review; tier=B1; direction=null; claims=2.
- Ghojazadeh 2024: outcome=immune; directness=review; tier=B1; direction=unclear; claims=2.
- Ding 2025: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=134.
- Konopka 2019: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=84.
- Han 2016: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=83.
- Prior 2014: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=73.
- Rajabi 2024: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=70.
- Emmel 2025: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=67.
- Kobayashi 2021: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=64.
- Healy 2024: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=56.
- Hugenschmidt 2019: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=50.
- Oliveira 2018: outcome=safety comorbidity; directness=indirect; tier=B2; direction=null; claims=47.
- Wood 2023: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=39.
- Wyngaert 2018: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=38.
- Bakali 2023: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=36.
- Santos 2024: outcome=muscle function; directness=indirect; tier=B2; direction=unclear; claims=33.
- Gaitan 2021: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=28.
- Morita 2019: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=22.
- Davis 2017: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=19.
- ZURE 2025: outcome=deficiency prevalence; directness=review; tier=B2; direction=unclear; claims=19.
- Tanaka 2018: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=14.
- Li 2024: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=12.
- Pawar 2025: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=8.
- Jannas-Vela 2023: outcome=muscle function; directness=indirect; tier=B2; direction=null; claims=6.
- Silva 2023: outcome=cardiometabolic; directness=protocol; tier=D1; direction=null; claims=18.

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Severity 4 null vs negative: Silva 2023 vs Swift 2012; Swift 2012 (negative on cardiometabolic) vs Silva 2023 (null on cardiometabolic) — partial conflict
- Severity 4 null vs negative: Li 2024 vs Swift 2012; Swift 2012 (negative on cardiometabolic) vs Li 2024 (null on cardiometabolic) — partial conflict
- Severity 4 null vs negative: Tanaka 2018 vs Swift 2012; Swift 2012 (negative on cardiometabolic) vs Tanaka 2018 (null on cardiometabolic) — partial conflict
- Severity 4 null vs negative: Swift 2012 vs Gelinas 2017; Swift 2012 (negative on cardiometabolic) vs Gelinas 2017 (null on cardiometabolic) — partial conflict
- Severity 4 null vs positive: Ehlers 2025 vs Kleinloog 2022; Kleinloog 2022 (positive on contextual other) vs Ehlers 2025 (null on contextual other) — partial conflict
- Severity 4 null vs positive: Zhou 2026 vs Kleinloog 2022; Kleinloog 2022 (positive on contextual other) vs Zhou 2026 (null on contextual other) — partial conflict
- Severity 4 null vs positive: Liu-Ambrose 2010 vs Lo 2021; Lo 2021 (positive on muscle function) vs Liu-Ambrose 2010 (null on muscle function) — partial conflict
- Severity 4 null vs positive: Alkhateeb 2020 vs Lo 2021; Lo 2021 (positive on muscle function) vs Alkhateeb 2020 (null on muscle function) — partial conflict

## Conclusion

For aerobic exercise training effects, the final interpretation is deliberately tiered: the retained direct, adjacent, and context evidence profile defines a bounded evidence rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general efficacy endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent/context evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support aerobic exercise training effects as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone longevity intervention with proven hard clinical-outcome effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

## References

- **MoralesPalomo 2023.** _Efficacy of morning versus afternoon aerobic exercise training on reducing metabolic syndrome components: A randomized controlled trial._ The Journal of Physiology, 2023. DOI: 10.1113/JP285366 PMID: 38015017.
- **Kleinloog 2022.** _Aerobic exercise training improves not only brachial artery flow‐mediated vasodilatation but also carotid artery reactivity: A randomized controlled, cross‐over trial in older men._ Physiological Reports, 2022. DOI: 10.14814/phy2.15395 PMID: 36030401.
- **Ding 2025.** _Effects of Aerobic Exercise Training in Hypoxia Versus Normoxia on Body Composition and Metabolic Health in Overweight and/or Obese Populations: an Updated Meta-Analysis._ Sports Medicine - Open, 2025. DOI: 10.1186/s40798-025-00918-6 PMID: 41032148.
- **Sloan 2018.** _Aerobic Exercise Training and Inducible Inflammation: Results of a Randomized Controlled Trial in Healthy, Young Adults._ Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018. DOI: 10.1161/JAHA.118.010201 PMID: 30371169.
- **Konopka 2019.** _Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults._ Aging Cell, 2019. DOI: 10.1111/acel.12880 PMID: 30548390.
- **Han 2016.** _Association of serum myokines and aerobic exercise training in patients with spinal cord injury: an observational study._ BMC Neurology, 2016. DOI: 10.1186/s12883-016-0661-9 PMID: 27534935.
- **Prior 2014.** _Increased Skeletal Muscle Capillarization After Aerobic Exercise Training and Weight Loss Improves Insulin Sensitivity in Adults With IGT._ Diabetes Care, 2014. DOI: 10.2337/dc13-2358 PMID: 24595633.
- **Rajabi 2024.** _The effect of 12 weeks of aerobic exercise training with or without saffron supplementation on diabetes‐specific markers and inflammation in women with type 2 diabetes: A randomized double‐blind placebo‐controlled trial._ European Journal of Sport Science, 2024. DOI: 10.1002/ejsc.12125 PMID: 38874882.
- **Emmel 2025.** _Feasibility of an unsupervised aerobic exercise training program for participants with persistent symptoms after SARS-CoV-2 infection._ Scientific Reports, 2025. DOI: 10.1038/s41598-025-13905-4 PMID: 40770036.
- **Alzahrani 2023.** _Feasibility and Efficacy of Low-to-Moderate Intensity Aerobic Exercise Training in Reducing Resting Blood Pressure in Sedentary Older Saudis with Hypertension Living in Social Home Care: A Pilot Randomized Controlled Trial._ Medicina, 2023. DOI: 10.3390/medicina59061171 PMID: 37374375.
- **Kobayashi 2021.** _The Effect of Aerobic Exercise Training Frequency on Arterial Stiffness in a Hyperglycemic State in Middle-Aged and Elderly Females._ Nutrients, 2021. DOI: 10.3390/nu13103498 PMID: 34684499.
- **Healy 2024.** _The Effects of Aerobic Exercise Training on Testosterone Concentration in Individuals Who are Obese or Have Type 2 Diabetes: A Systematic Review and Meta-Analysis._ Sports Medicine - Open, 2024. DOI: 10.1186/s40798-024-00781-x PMID: 39467940.
- **Lo 2021.** _Effects of Individualized Aerobic Exercise Training on Physical Activity and Health-Related Physical Fitness among Middle-Aged and Older Adults with Multimorbidity: A Randomized Controlled Trial._ International Journal of Environmental Research and Public Health, 2021. DOI: 10.3390/ijerph18010101 PMID: 33375668.
- **Hugenschmidt 2019.** _Cognitive effects of adding caloric restriction to aerobic exercise training in older adults with obesity._ Obesity (Silver Spring, Md.), 2019. DOI: 10.1002/oby.22525 PMID: 31199592.
- **Burchert 2022.** _Aerobic Exercise Training Response in Preterm-Born Young Adults with Elevated Blood Pressure and Stage 1 Hypertension: A Randomized Clinical Trial._ American Journal of Respiratory and Critical Care Medicine, 2022. DOI: 10.1164/rccm.202205-0858OC PMID: 36459100.
- **Oliveira 2018.** _Safety and Efficacy of Aerobic Exercise Training Associated to Non-Invasive Ventilation in Patients with Acute Heart Failure._ Arquivos Brasileiros de Cardiologia, 2018. DOI: 10.5935/abc.20180039 PMID: 29538506.
- **Wood 2023.** _Estimating the Effect of Aerobic Exercise Training on Novel Lipid Biomarkers: A Systematic Review and Multivariate Meta-Analysis of Randomized Controlled Trials._ Sports Medicine (Auckland, N.z.), 2023. DOI: 10.1007/s40279-023-01817-0 PMID: 36862340.
- **Wyngaert 2018.** _The effects of aerobic exercise on eGFR, blood pressure and VO 2 peak in patients with chronic kidney disease stages 3-4: A systematic review and meta-analysis._ PLoS ONE, 2018. DOI: 10.1371/journal.pone.0203662 PMID: 30204785.
- **Bakali 2023.** _Effect of aerobic exercise training on pulse wave velocity in adults with and without long-term conditions: a systematic review and meta-analysis._ Open Heart, 2023. DOI: 10.1136/openhrt-2023-002384 PMID: 38101857.
- **Santos 2024.** _Aerobic exercise training combined with local strength exercise restores muscle blood flow and maximal aerobic capacity in long-term Hodgkin lymphoma survivors._ American Journal of Physiology - Heart and Circulatory Physiology, 2024. DOI: 10.1152/ajpheart.00132.2024 PMID: 38639741.
- **Gaitan 2021.** _Effects of Aerobic Exercise Training on Systemic Biomarkers and Cognition in Late Middle-Aged Adults at Risk for Alzheimer’s Disease._ Frontiers in Endocrinology, 2021. DOI: 10.3389/fendo.2021.660181 PMID: 34093436.
- **Morita 2019.** _Aerobic Exercise Training with Brisk Walking Increases Intestinal Bacteroides in Healthy Elderly Women._ Nutrients, 2019. DOI: 10.3390/nu11040868 PMID: 30999699.
- **ZURE 2025.** _The effect of blood flow restricted aerobic exercise training on pain, functional status, quality of life and hormonal response to exercise in fibromyalgia patients: a randomized double-blind study._ European Journal of Physical and Rehabilitation Medicine, 2025. DOI: 10.23736/S1973-9087.25.08817-3 PMID: 40433671.
- **Davis 2017.** _Economic evaluation of aerobic exercise training in older adults with vascular cognitive impairment: PROMoTE trial._ BMJ Open, 2017. DOI: 10.1136/bmjopen-2016-014387 PMID: 28360247.
- **Silva 2023.** _Anodal transcranial direct current stimulation associated with aerobic exercise on the functional and physical capacity of patients with heart failure with reduced ejection fraction: ELETRIC study protocol._ Trials, 2023. DOI: 10.1186/s13063-023-07694-2 PMID: 37974293.
- **Hansen 2021.** _Effect of aerobic exercise training on asthma control in postmenopausal women (the ATOM-study): protocol for an outcome assessor, randomised controlled trial._ BMJ Open, 2021. DOI: 10.1136/bmjopen-2021-049477 PMID: 33888532.
- **Tanaka 2018.** _The impact of aerobic exercise training with vascular occlusion in patients with chronic heart failure._ ESC Heart Failure, 2018. DOI: 10.1002/ehf2.12285 PMID: 29575708.
- **Swift 2012.** _The effect of different doses of aerobic exercise training on endothelial function in postmenopausal women with elevated blood pressure: results from the DREW study._ Br J Sports Med, 2012. DOI: 10.1136/bjsports-2011-090025 PMID: 21947813.
- **Jespersen 2023.** _Effect of aerobic exercise training on the fat fraction of the liver in persons with chronic hepatitis B and hepatic steatosis: Trial protocol for a randomized controlled intervention trial— The FitLiver study._ Trials, 2023. DOI: 10.1186/s13063-023-07385-y PMID: 37312098.
- **Li 2024.** _The effect of moderate and vigorous aerobic exercise training on the cognitive and walking ability among stroke patients during different periods: A systematic review and meta-analysis._ PLOS ONE, 2024. DOI: 10.1371/journal.pone.0298339 PMID: 38394189.
- **Alkhateeb 2020.** _Effects of football versus aerobic exercise training on muscle architecture in healthy men adults: a study protocol of a two-armed randomized controlled trial._ Trials, 2020. DOI: 10.1186/s13063-020-04797-y PMID: 33298145.
- **Ehlers 2025.** _Enhancing cognitive function in breast cancer survivors through community-based aerobic exercise training: protocol for a Hybrid Type I effectiveness–implementation study employing a randomised controlled design._ BMJ Open, 2025. DOI: 10.1136/bmjopen-2025-104378 PMID: 40659404.
- **Zhou 2026.** _Telemedicine-based individualised aerobic exercise training in Chinese adults with inactive or mildly active inflammatory bowel disease: study protocol for a single-centre, semi-crossover randomised controlled trial._ BMJ Open, 2026. DOI: 10.1136/bmjopen-2025-103297 PMID: 41490862.
- **Pawar 2025.** _Effectiveness of aerobic exercise training in patients with obstructive sleep apnea: a systematic review and meta-analysis._ European Archives of Oto-Rhino-Laryngology, 2025. DOI: 10.1007/s00405-025-09436-3 PMID: 40329037.
- **Raichlen 2020.** _Effects of simultaneous cognitive and aerobic exercise training on dual-task walking performance in healthy older adults: results from a pilot randomized controlled trial._ BMC Geriatrics, 2020. DOI: 10.1186/s12877-020-1484-5 PMID: 32122325.
- **Jannas-Vela 2023.** _Role of specialized pro-resolving mediators on inflammation, cardiometabolic health, disease progression, and quality of life after omega-3 PUFA supplementation and aerobic exercise training in individuals with rheumatoid arthritis: a randomized 16-week, placebo-controlled interventional trial *._ F1000Research, 2023. DOI: 10.12688/f1000research.138392.1 PMID: 38778807.
- **Gelinas 2017.** _Aerobic exercise training does not alter vascular structure and function in chronic obstructive pulmonary disease._ Exp Physiol, 2017. DOI: 10.1113/ep086379 PMID: 28857336.
- **Ghojazadeh 2024.** _The effects of aerobic exercise training on inflammatory markers in adult tobacco smokers: A systematic review and meta-analysis of randomized controlled trials._ Respir Med, 2024. DOI: 10.1016/j.rmed.2024.107732 PMID: 38971338.
- **Liu-Ambrose 2010.** _Promotion of the mind through exercise (PROMoTE): a proof-of-concept randomized controlled trial of aerobic exercise training in older adults with vascular cognitive impairment._ BMC Neurology, 2010. DOI: 10.1186/1471-2377-10-14 PMID: 20158920.

### Background References

*Canonical reference values and methodological references cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).*

- **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ (methodological reference) DOI: 10.1371/journal.pmed.0020124 PMID: 16060722.

{
  "article_type": "evidence_map",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "916db12e-2ce9-4e69-ac9c-5afbd2173116",
  "title": "Research Synthesis: Aerobic Exercise Training Effects \u2014 full paper"
}